The FDA approved Tauklarify on Aug. 13, 2026, to image tau tangles in adults with cognitive impairment being evaluated for Alzheimer's. For people with mild cognitive impairment, the news means doctors can now order a tau PET scan to help place memory changes in the Alzheimer's process.
Tau tangles are twisted clumps of tau protein inside brain cells. They are a hallmark lesion of Alzheimer's disease. Tauklarify, formerly called MK-6240, is an F-18-labeled tracer that is injected before a PET scan and binds those clumps, according to the Lantheus approval announcement Lantheus press release.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What does this scan add for MCI?
- How well do readers interpret the images?
- What happens at the imaging center?
- What should you ask your doctor?
What does this scan add for MCI?
Mild cognitive impairment means memory or thinking changes are measurable but daily function remains largely intact. Causes vary, and Alzheimer's is only one possibility. Approval covered adults across the impairment spectrum, including early stages such as mild cognitive impairment.
A tau scan does not replace memory testing, medical history, or amyloid testing. It adds biological information about tau spread. That can help a clinician characterize where a patient stands in Alzheimer's progression.
How well do readers interpret the images?
Efficacy came from two studies with more than 500 participants. Five blinded readers scored each scan as positive or negative. Positive agreement ranged from 68% to 88%, while negative agreement ranged from 93% to 99%, with high agreement among readers, as reported by NeurologyLive NeurologyLive report. That pattern matters for MCI decisions.
Negative scans were read more consistently than positive scans. A scan is therefore one piece of evidence, not a stand-alone diagnosis. A positive Tauklarify scan does not by itself confirm tau pathology. A negative scan does not rule it out. Safety and effectiveness are not established for tau conditions other than Alzheimer's, according to Reuters and the product label Reuters report.
What happens at the imaging center?
The test requires a center equipped to handle radioactive drugs and PET imaging. A clinician first determines whether tau imaging fits the diagnostic question. Scheduling, insurance coverage, travel, and radiation precautions deserve direct discussion.
Practical use involves a single 185 MBq, or 5 mCi, intravenous dose before PET imaging. Common reported reactions are headache and nausea. The procedure involves radiation exposure.
- Ask whether the center offers Tauklarify and reads tau PET scans routinely
- Avoid tobacco and CYP1A2 inducers for seven days before dosing, per labeling
- Bring a complete drug, supplement, smoking, and medical history
- Plan for IV placement, quiet waiting time, and scan time
What should you ask your doctor?
Ask why tau imaging would change your care plan. For some patients, it clarifies eligibility for treatment trials or support services. For others, watchful follow-up may remain reasonable.
Ask how the result will be combined with cognition, function, MRI, amyloid status, and other health conditions. Ask what a positive, negative, or uncertain read would lead you to do next. Bring a family member or care partner to record the plan. The prescribing information lists dosing, radiation safety, headache and nausea, and the seven-day avoidance of tobacco and CYP1A2 inducers, according to Lantheus prescribing information.
You Might Also Like
- PrecivityAD2 and Younger-Onset Alzheimer’s Diagnosis in 2026: What People With Mild Cognitive Impairment Should Know About the News
- Vitamin Supplements in the 2026 WHO Dementia Guideline: What Is Established and What Is Still Being Studied for People With Mild Cognitive Impairment
- Healthy Diets in the 2026 WHO Dementia Guideline: What Is Established and What Is Still Being Studied for People With Mild Cognitive Impairment





